Literature DB >> 22826285

Successful target attainment of telavancin at elevated MICs: fact or fiction?

Andras Farkas.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22826285      PMCID： PMC3421611          DOI： 10.1128/AAC.00609-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Heather C Elliott; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Postantibiotic effects of telavancin against 16 gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-01-05       Impact factor: 5.191

3.  Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.

Authors:  Noe Reyes; Robert Skinner; Bret M Benton; Kevin M Krause; Josephine Shelton; Glenmar P Obedencio; Sharath S Hegde
Journal:  J Antimicrob Chemother       Date:  2006-05-30       Impact factor: 5.790

4.  Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.

Authors:  Noe Reyes; Robert Skinner; Koné Kaniga; Kevin M Krause; Josephine Shelton; Glenmar P Obedencio; Alexander Gough; Michael Conner; Sharath S Hegde
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.

Authors:  Maritza Barcia-Macay; Sandrine Lemaire; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  J Antimicrob Chemother       Date:  2006-10-24       Impact factor: 5.790

6.  Telavancin: in vitro activity against staphylococci in a biofilm model.

Authors:  Sarah Gander; Andrew Kinnaird; Roger Finch
Journal:  J Antimicrob Chemother       Date:  2005-06-21       Impact factor: 5.790

7.  Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.

Authors:  T P Lodise; J M Butterfield; S S Hegde; E Samara; S L Barriere
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

8.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191
  8 in total
  2 in total

1.  Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.

Authors:  Kristen L Bunnell; Manjunath P Pai; Monica Sikka; Susan C Bleasdale; Eric Wenzler; Larry H Danziger; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 2.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.